



September 25, 2017

Via EDGAR Correspondence

United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Attn: Ms. Irene Paik

**Re: Re: Ohr Pharmaceutical, Inc.
 Registration Statement on Form S-3
 Filed September 15, 2017
 File No. 333-220487**

Dear Ms. Paik:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, the undersigned registrant under the above-referenced registration statement hereby requests acceleration of the effective date of the registration statement to September 27, 2017, at 4:00 p.m., New York time, or as soon as practicable thereafter. Please notify our outside counsel, Joseph Walsh, Esq., by phone at (212) 704-6030, by fax at (212) 704-5919, or by email at joseph.walsh@troutman.com of the date and time that the registration statement has been declared effective.

Very truly yours,

Ohr Pharmaceutical, Inc.

By: /s/ Sam Backenroth

Name: Sam Backenroth

Title: Chief Financial Officer

cc: Dr. Jason Slakter, Chief Executive Officer, Ohr Pharmaceutical, Inc.
Aurora Cassirer, Esq. Troutman Sanders, LLP
Joseph Walsh, Esq., Troutman Sanders, LLP
